Bicara Therapeutics (BCAX) Net Equity Issued and Repurchased (2024 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Net Equity Issued and Repurchased of $161.8 million for Q1 2026, up 448.39% quarter-over-quarter from $29.5 million in Q4 2025.
Bicara Therapeutics (BCAX) Net Equity Issued and Repurchased (2024 - 2026) Analysis & Trends
Bicara Therapeutics' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $161.8 million for Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $161.8 million; the TTM figure through Mar 2026 stood at $190.2 million (changed N/A YoY), while the FY2025 annual figure was $29.5 million, down 91.13% from the prior year.
- Net Equity Issued and Repurchased for Q1 2026 stood at $161.8 million, up from $29.5 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $161.8 million in Q1 2026, with the low at -$1.1 million in Q4 2024.
- The 3-year median for Net Equity Issued and Repurchased is $29.5 million (2025), against an average of $63.4 million.
- Peak annual rise in Net Equity Issued and Repurchased reached 2903.99% in 2025, while the deepest fall reached 2903.99% in 2025.
- Bicara Therapeutics' Net Equity Issued and Repurchased stood at -$1.1 million in 2024, then soared by 2903.99% to $29.5 million in 2025, then surged by 448.39% to $161.8 million in 2026.
- Business Quant data shows BCAX's Net Equity Issued and Repurchased at $161.8 million in Q1 2026, $29.5 million in Q4 2025, and -$1.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 161.76 Mn |
| Mar 31, 2026 | 161.76 Mn |
| Dec 31, 2025 | 29.50 Mn |
| Dec 31, 2025 | 29.50 Mn |
| Dec 31, 2024 | -1.05 Mn |
| Dec 31, 2024 | -1.05 Mn |